Vaxcyte’s (PCVX) “Buy” Rating Reiterated at BTIG Research

Posted by Francis Steltz on Oct 8th, 2026

BTIG Research reiterated their buy rating on shares of Vaxcyte (NASDAQ:PCVX – Free Report) in a research note released on Monday, MarketBeat.com reports. BTIG Research currently has a $89.00 price objective on the stock.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Needham & Company LLC increased their price objective on shares of Vaxcyte from $110.00 to $122.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, October 2nd. Guggenheim boosted their target price on shares of Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a report on Monday. Finally, Bank of America decreased their target price on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research report on Monday, September 28th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $108.60.

Check Out Our Latest Report on PCVX

Vaxcyte Price Performance

NASDAQ:PCVX opened at $66.96 on Monday. Vaxcyte has a 1 year low of $39.87 and a 1 year high of $90.75. The stock’s 50 day simple moving average is $59.56 and its two-hundred day simple moving average is $56.49. The company has a market cap of $9.96 billion, a price-to-earnings ratio of -8.78 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same period in the prior year, the company earned ($1.22) EPS. As a group, analysts anticipate that Vaxcyte will post -8.07 EPS for the current year.

Insider Activity

In related news, EVP Jim Wassil sold 18,000 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $86.74, for a total transaction of $1,561,320.00. Following the sale, the executive vice president owned 145,435 shares in the company, valued at approximately $12,615,031.90. This represents a 11.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total value of $538,900.00. Following the completion of the sale, the chief financial officer owned 105,176 shares of the company’s stock, valued at approximately $5,667,934.64. This represents a 8.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 92,890 shares of company stock worth $6,320,569. Company insiders own 3.30% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds and other institutional investors have recently made changes to their positions in the company. First Light Asset Management LLC boosted its stake in shares of Vaxcyte by 143.4% during the 2nd quarter. First Light Asset Management LLC now owns 345,157 shares of the company’s stock worth $20,064,000 after purchasing an additional 203,373 shares during the period. Engineers Gate Manager LP bought a new position in Vaxcyte during the 2nd quarter valued at about $1,906,000. IFP Advisors Inc grew its holdings in Vaxcyte by 72.8% during the 2nd quarter. IFP Advisors Inc now owns 560 shares of the company’s stock valued at $33,000 after purchasing an additional 236 shares during the last quarter. Arizona State Retirement System raised its position in Vaxcyte by 4.3% in the 2nd quarter. Arizona State Retirement System now owns 33,755 shares of the company’s stock worth $1,962,000 after purchasing an additional 1,394 shares during the period. Finally, Nykredit A S purchased a new stake in Vaxcyte in the 2nd quarter worth about $280,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Trending Headlines about Vaxcyte

Here are the key news stories impacting Vaxcyte this week:

Positive Sentiment: Vaxcyte reported a positive Phase 3 result for its VAX-31 pneumococcal vaccine candidate in adults. The late-stage win strengthens the program’s regulatory and commercial prospects and prompted bullish commentary that the company had reached a potential “blue-sky” outcome. Vaxcyte leaps on positive Phase III trial of VAX-31
Positive Sentiment: Analysts remain constructive following the clinical update. Needham assigned Vaxcyte a $122 price target, while BTIG reaffirmed its Buy rating, indicating substantial anticipated upside if VAX-31 continues to advance successfully. Vaxcyte given new price target at Needham
Positive Sentiment: The company priced a financing consisting of $500 million of common stock and pre-funded warrants plus $500 million of 1.50% convertible senior notes due 2032. The proceeds should provide substantial funding for clinical development and commercialization preparations, while the relatively low coupon limits near-term interest expense. Vaxcyte announces pricing of concurrent offerings
Neutral Sentiment: Options activity was unusually heavy, with investors purchasing 8,093 put contracts—about 259% of typical volume—suggesting increased hedging or bearish speculation, but not necessarily a change in the company’s fundamentals.
Negative Sentiment: The equity issuance, pre-funded warrants and potentially convertible notes will increase the share count or create future dilution. The financing was priced at $64 per share, below the stock’s recent trading levels, contributing to selling pressure despite the positive trial news.
Neutral Sentiment: Chief Accounting Officer Elvia Cowan and EVP Jim Wassil sold 19,000 and 18,000 shares, respectively, under pre-arranged Rule 10b5-1 plans. The transactions reduce their holdings but were scheduled sales and therefore provide limited insight into current management sentiment.

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.